Predicting Treatment Effects of Interferon in HCV Patients
Author Information
Author(s): Huang Tao, Tu Kang, Shyr Yu, Wei Chao-Chun, Xie Lu, Li Yi-Xue
Primary Institution: Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
Hypothesis
Can time series microarray gene expression profiles predict the treatment effects of interferon and ribavirin in HCV infected patients?
Conclusion
The study developed a model that accurately predicts treatment outcomes for HCV patients based on gene expression profiles over time.
Supporting Evidence
- The model predicted treatment effects for all Caucasian American patients at an early time point.
- The prediction accuracy for African-American patients was 85.7%.
- Thirty potential biomarkers were identified that may influence treatment response.
Takeaway
Doctors can use blood tests to see how well a medicine is working for patients with hepatitis C, helping them decide if they should keep taking it.
Methodology
The study analyzed gene expression profiles from 69 patients over multiple time points using a decision tree model.
Potential Biases
Potential bias due to differences in responses between racial groups.
Limitations
The model performed better for Caucasian American patients compared to African-American patients.
Participant Demographics
33 African-American and 36 Caucasian American patients with chronic HCV genotype 1 infection.
Statistical Information
P-Value
0.00001 for all patients, 0.001 for AA patients, 0.0001 for CA patients
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website